Edition:
United States

Arbutus Biopharma Corp (ABUS.OQ)

ABUS.OQ on NASDAQ Stock Exchange Global Select Market

4.75USD
13 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.75
Open
$4.80
Day's High
$4.95
Day's Low
$4.55
Volume
61,854
Avg. Vol
67,747
52-wk High
$8.25
52-wk Low
$2.35

Chart for

About

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is... (more)
No analyst recommendations are available for .

Overall

Beta: 0.72
Market Cap(Mil.): $493.14
Shares Outstanding(Mil.): 55.03
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Arbutus’ LNP licensee Alnylam initiates rolling submission of NDA for Patisiran

* Arbutus’ LNP licensee Alnylam initiates rolling submission of New Drug Application (NDA) to U.S. Food and drug Administration (fda) for Patisiran

Nov 16 2017

BRIEF-Arbutus’LNP Licensee Alnylam receives accelerated assessment of patisiran from European Medicines Agency

* Arbutus’ LNP Licensee Alnylam receives accelerated assessment of patisiran from European Medicines Agency (EMA) Source text for Eikon: Further company coverage:

Nov 13 2017

BRIEF-Arbutus Biopharma reports Q3 loss per share $0.21

* Arbutus Biopharma Corp announces corporate update and third quarter 2017 financial results

Nov 02 2017

BRIEF-Gritstone Oncology and Arbutus Biopharma announce LNP technology licensing agreement

* Gritstone Oncology and Arbutus Biopharma announce LNP technology licensing agreement to develop novel RNA-based personalized neoantigen immunotherapies for cancer patients

Oct 18 2017

BRIEF-Arbutus to Receive $116 Million Strategic Investment from Roivant Sciences

* Signed share purchase agreement with Roivant Sciences for sale of convertible preferred shares for $116.4 million

Oct 02 2017

BRIEF-Arbutus announces topline results for ARB-1467 phase II Cohort 4

* Arbutus Biopharma Corp announces topline results for ARB-1467 phase ii cohort 4

Sep 25 2017

BRIEF-Arbutus Biopharma Q2 loss per share $0.33

* Arbutus announces corporate update and second quarter 2017 financial results

Aug 03 2017

BRIEF-Arbutus expects to take two experimental hep B drugs into human studies by mid-2018 - CEO

* Arbutus Biopharma expects to take two of its preclinical hep B drugs-in-development into human studies by mid-2018 - ceo Further company coverage:

Jul 27 2017

BRIEF-Arbutus announces conclusion of LNP license agreement with Alexion

* Arbutus announces conclusion of LNP license agreement with Alexion

Jul 27 2017

Earnings vs. Estimates